Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

05 APR 2022

FDA ADVISORY
No. ~~2022~~0780

TO : **ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

SUBJECT : **Public Health Warning Against the Purchase and Use of the following Verified Counterfeit Drug Products:**

1. **Paracetamol (Biogesic®) 500 mg Tablet**
2. **Phenylephrine Hydrochloride / Chlorphenamine Maleate / Paracetamol (Neozep® Forte) 10 mg / 2 mg / 500 mg Tablet**

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following products:

AUTHENTIC



COUNTERFEIT



Counterfeit – The tablet, security mark, knurling, and print appearance are different from standard.

Figure 1. Comparison between the Authentic and Counterfeit Paracetamol (Biogesic®) 500 mg Tablet (Lot Nos. 63596821 and 56202338)

Civic Drive, Filinvest City, Alabang 1781 Muntinlupa, Philippines
Trunk Line +63 2 857 1900 Fax +63 2 807 0751
Website: www.fda.gov.ph Email: info@fda.gov.ph

AUTHENTIC



COUNTERFEIT



Counterfeit – The tablet, logo, security mark, knurling, print color and appearance are different from standard.

Figure 2. Comparison between the Authentic and Counterfeit Paracetamol Phenylephrine Hydrochloride / Chlorphenamine Maleate / Paracetamol (Neozep® Forte) 10 mg/ 2 mg/ 500 mg Tablet (Lot Nos. 13121123 and 19670411)

All healthcare professionals and the general public are hereby warned as to the availability of these counterfeit drug products in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug products only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit products with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug products will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via ereport@fda.gov.ph. You may also call the Center for Drug Regulation and Research at telephone number **(02) 8809-5596**. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH and fill out all the required fields

Dissemination of the information to all concerned is requested.

DR. OSCAR G. GUTIERREZ, JR.
Officer-in-Charge Director General

DTN: 20220308081442